Objectives
What is the study measuring?
Primary Outcome Measure: Number of participants that experienced neurotoxicity during the first cycle of blinatumomab therapy. Record occurrence and severity of neurotoxicity based on CTCAE criteria
Secondary Outcome Measure: Number of participants that experienced cytokine release syndrome during the first cycle of blinatumomab therapy. Record occurrence and severity of cytokine release syndrome based on CTCAE criteria.
Number of participants with a response of complete remission and MRD negativity at the end of cycle 1.Conduct disease restaging assessments, such as bone marrow biopsies and lumbar punctures, to determine response to treatment.